- Home
- BIAF vs SPRB Comparison
BIAF vs SPRB Comparison
Compare BIAF & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- SPRB
- Stock Information
- Founded
- BIAF 2014
- SPRB 2014
- Country
- BIAF United States
- SPRB United States
- Employees
- BIAF N/A
- SPRB N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- BIAF Health Care
- SPRB Health Care
- Exchange
- BIAF Nasdaq
- SPRB Nasdaq
- Market Cap
- BIAF 14.5M
- SPRB 15.7M
- IPO Year
- BIAF 2022
- SPRB 2020
- Fundamental
- Price
- BIAF $0.67
- SPRB $0.38
- Analyst Decision
- BIAF Strong Buy
- SPRB Hold
- Analyst Count
- BIAF 1
- SPRB 7
- Target Price
- BIAF $6.00
- SPRB $2.17
- AVG Volume (30 Days)
- BIAF 298.9K
- SPRB 552.0K
- Earning Date
- BIAF 11-14-2024
- SPRB 03-12-2025
- Dividend Yield
- BIAF N/A
- SPRB N/A
- EPS Growth
- BIAF N/A
- SPRB N/A
- EPS
- BIAF N/A
- SPRB N/A
- Revenue
- BIAF $9,367,785.00
- SPRB $7,101,000.00
- Revenue This Year
- BIAF $285.51
- SPRB N/A
- Revenue Next Year
- BIAF $20.05
- SPRB N/A
- P/E Ratio
- BIAF N/A
- SPRB N/A
- Revenue Growth
- BIAF 2813.87
- SPRB N/A
- 52 Week Low
- BIAF $0.64
- SPRB $0.34
- 52 Week High
- BIAF $3.62
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- BIAF 26.36
- SPRB 41.95
- Support Level
- BIAF $0.64
- SPRB $0.35
- Resistance Level
- BIAF $1.01
- SPRB $0.39
- Average True Range (ATR)
- BIAF 0.07
- SPRB 0.03
- MACD
- BIAF -0.01
- SPRB 0.00
- Stochastic Oscillator
- BIAF 5.99
- SPRB 36.60
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).